

**Office of National Drug Control Policy
Executive Office of the President
1800 G Street, NW
Washington, DC 20503**

**Fiscal Year (FY) 2023 Competitive Cooperative Agreement Solicitation
Combating Overdose through Community-Level Intervention
Notice of Funding Opportunity Number: CCL-CCL-23-001
Assistance Listing Number: 95.007
Release Date: July 31, 2023**

The Office of National Drug Control Policy (ONDCP), Executive Office of the President, is seeking applications from public nonprofit institutions/organizations (includes institutions of higher education and hospitals) to:

- (1) Undertake research activities that would entail implementing and evaluating community-based efforts to fight the drug overdose epidemic; and
- (2) Support and promote the partnership of law enforcement and public health agencies, whose collaboration is critical to reducing drug overdose and other harms of substance (mis)use.

Deadline

Applicants must register with [Grants.gov](#) prior to submitting an application. All applications must be submitted and applicants must be in receipt of a successful validation message in [Grants.gov](#) by 5:00 p.m., Eastern Time, on August 31, 2023.

Contact Information

For technical assistance with submitting an application, contact the [Grants.gov](#) Customer Support Hotline at (800) 518-4726 or (606) 545-5035, or via email to support@grants.gov. The [Grants.gov](#) Customer Support Hotline hours of operation are 24 hours a day, 7 days a week, except federal holidays.

Applicants who experience unforeseen [Grants.gov](#) technical issues that prevent them from submitting their application by the deadline must submit all required application materials to jdelano@ondcp.eop.gov no later than 5:00 p.m. on August 31, 2023 via email (including a brief explanation of the technical issues that prevented application through [Grants.gov](#)) and request approval for acceptance of the separate application.

For assistance with any other requirements of this solicitation, applicants may contact Jayme A. Delano, Office of National Drug Control Policy, by telephone at (202) 395-6794 or by email at jdelano@ondcp.eop.gov.

Eligibility

Eligible Applicant

- Public nonprofit institutions/organizations (Institutions of Higher Education (Public and/or Private))
- Hospitals (Private nonprofit Institutions/organizations)

Eligibility Criteria

- Applicants must have expert knowledge and extensive experience in conducting research and analysis.
- Applicants must have expert knowledge and experience developing or enhancing new or ongoing programs that aim to reduce drug overdose and related harms through strategic, evidence-based approaches.
- Applicants must partner with a regional High Intensity Drug Trafficking Area (HIDTA) Program, and applications must include a letter of support/commitment from the participating HIDTA and signed by the sponsoring HIDTA Director.
- In order to be eligible to receive funding under this award, recipients must be legally recognized as a public or private nonprofit institution/organization (includes institutions of higher education and hospitals).

A. Program Description

Overview

Drug overdoses remain the leading cause of injury-related death in the United States.¹ CDC estimates that nearly 110,000 Americans have died from a drug overdose in the 12-month period ending December 2022. While COVID-19 contributed to factors such as reduced access to healthcare services and increased stress levels due to isolation, the United States also experienced changes in the types and purities of drugs on the market during this time². Most recently, the increase in overdose deaths has been linked to the rapid increase in synthetic opioids, including illicitly manufactured fentanyl (IMF), and a resurgence of stimulants, particularly methamphetamine, into the illicit drug supply.

Counterfeit pills continue to pervade the illicit drug market and threaten more lives each year. In 2022, the U.S. Drug Enforcement Administration (DEA) alerted the public that 6 out of 10 fentanyl-laced counterfeit prescription pills contained a potentially deadly dose of fentanyl, up from 4 out of 10 in 20A³. DEA laboratories estimated the seizure of 379 million pills in 2022⁴.

In November 2022, the U.S. Food and Drug Administration (FDA) released a statement alerting healthcare professionals to the risks associated with xylazine exposure⁵. Xylazine is a non-opiate sedative, analgesic and muscle relaxant only authorized in the U.S. for veterinary use⁶. Xylazine has been detected in an ever-growing number of drug overdose deaths, especially among polysubstance overdose fatalities⁷. Prolonged exposure to xylazine use is associated with delayed wound healing and high risk of infection⁸. In April 2023, ONDCP officially designated fentanyl adulterated or associated with xylazine as an emerging threat to the United States.

¹ Centers for Disease Control and Prevention (CDC), National Center for Injury Prevention and Control. (2022, February 14). Understanding Drug Overdoses and Deaths. Retrieved from <https://www.cdc.gov/drugoverdose/epidemic/index.html>.

² Ghose, R., Forati, A.M. & Mantsch, J.R. Impact of the COVID-19 Pandemic on Opioid Overdose Deaths: A Spatiotemporal Analysis. *J Urban Health* 99, 316–327 (2022). <https://doi.org/10.1007/s11524-022-00610-0>.

³ U.S. Drug Enforcement Administration. (2022, November 21). DEA Laboratory Testing Reveals that 6 out of 10 Fentanyl-Laced Fake Prescription Pills Now Contain a Potentially Lethal Dose of Fentanyl [Press release]. <https://www.dea.gov/alert/dea-laboratory-testing-reveals-6-out-10-fentanyl-laced-fake-prescription-pillsnow-contain>

⁴ U.S. Drug Enforcement Administration. (2022, December 20). Drug Enforcement Administration Announces the Seizure of Over 379 million Deadly Doses of Fentanyl in 2022 [Press release]. <https://www.dea.gov/pressreleases/2022/12/20/drug-enforcement-administration-announces-seizure-over-379-million-deadly>

⁵ U.S. Food and Drug Administration. (2022, November 8). FDA alerts health care professionals of risks to patients exposed to xylazine in illicit drugs. <https://www.fda.gov/drugs/drug-safety-and-availability/fdaalerts-health-care-professionals-risks-patients-exposed-xylazine-illicit-drugs>.

⁶ U.S. Drug Enforcement Administration. (2022, December 21). The Growing Threat of Xylazine and its Mixture with Illicit Drugs: DEA Joint Intelligence Report, October 2022. <https://www.dea.gov/documents/2022/2022-12/2022-12-21/growing-threat-xylazine-and-its-mixture-illicit-drugs>.

⁷ U.S. Drug Enforcement Administration. (2022, December 21). The Growing Threat of Xylazine and its Mixture with Illicit Drugs: DEA Joint Intelligence Report, October 2022. <https://www.dea.gov/documents/2022/2022-12/2022-12-21/growing-threat-xylazine-and-its-mixture-illicit-drugs>.

⁸ Friedman, J., Montero, F., Bourgois, P., Wahbi, R., Dye, D., Goodman-Meza, D., & Shover, C. (2022). Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. *Drug and alcohol dependence*, 233, 109380. <https://doi.org/10.1016/j.drugalcdep.2022.109380>

The availability and composition of new synthetic opioids, as well as other emerging substances, require new and innovative responses, reliable data collection and continuous monitoring of the shifting factors contributing to drug overdose deaths. With an average of more than 250 lives lost each day in the United States to drug overdose, the epidemic demands a continued sense of urgency in response⁹. Preparing regional and community leaders to respond effectively to the public health emergency that is today's drug overdose crisis is essential for achieving the shared goal of preventing fatal overdose and saving lives.

ONDCP expects to award one federal cooperative agreement under the Combating Overdose through Community-Level Intervention Initiative (COCLI) for a 1-year period, beginning approximately September 2023. The successful non-federal entity (NFE) will conduct research activities that entail implementing and evaluating community-based efforts to fight the overdose epidemic. These activities will be focused on the regions of the United States with some of the highest rates of fatal and non-fatal overdoses and will work to coordinate the often-decentralized state and local efforts to assess and respond to overdoses.

Efforts will also support and promote the partnership of law enforcement and public health agencies, as coordination and collaboration between these two groups is proving critical to addressing this epidemic. Efforts will also align with and be informed by related projects currently being conducted by ONDCP and CDC, and both agencies will work closely with the successful NFE. In particular, work conducted under this initiative will entail partnership with federally designated High Intensity Drug Trafficking Area (HIDTA) Programs, which are funded by ONDCP and currently partner with the CDC under the Overdose Response Strategy initiative.

Goals, Objectives and What the Government is Supporting

The assistance provided under this award will support the NFE's performance of the award and fulfillment of the following performance areas:

- Research and analyze 1) a range of existing community-based efforts to address drug overdoses and 2) current evidence-based and proven strategies to reduce drug overdose deaths and related harms;
- Using the evidence-based approaches previously identified, implement or enhance community-based new or ongoing programs that aim to reduce drug overdose, particularly in the regions of the United States with the highest rates of fatal and non-fatal drug overdoses (priority will be given to proposals that make funding available to at least eight communities via subawards);
- Once implemented, support the evaluation of these community-based efforts to assess their efficacy in reducing drug overdose and other harms of substance (mis)use, particularly in the regions of the United States with the highest rates of fatal and non-fatal drug overdoses;

⁹ Senate Health, Education, Labor, and Pensions Committee. (2022, July 26). Fighting fentanyl: The federal response to a growing crisis. Centers for Disease Control and Prevention (CDC). Retrieved from <https://www.cdc.gov/washington/testimony/2022/t20220726.htm>

- Support and promote collaboration between public safety and public health agencies to ensure that drug overdose reduction efforts are aligned and that communities benefit from a comprehensive and coordinated response; and
- Provide technical assistance to support implementation, evaluation, and reporting by prospective subaward recipients.

Authorizing Statutes and Governing Regulations Applicable to this Funding Opportunity: The authority for this opportunity is the SUPPORT for Patients and Communities Act, (Pub. L. No. 115-271), 21 U.S.C. §§ 1701 *et seq.* and the Consolidated Appropriations Act, 2023 (Public Law 117-328). *The Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* are applicable to the government and applicants, cooperative agreement applications, and cooperative agreement awards to non-federal entities. *See* 2 C.F.R. Part 200 *et seq.*, as adopted in full by ONDCP via 2 C.F.R. Part 3603 *et seq.*

B. Federal Award Information

ONDCP expects to award one federal cooperative agreement under the Combating Overdose through Community-Level Intervention Initiative (COCLI), for a 1-year period, beginning approximately September 2023.

All applications and awards are subject to such additional requirements expressed in governing law. *See* 2 C.F.R. Part 200 *et seq.*

ONDCP expects that it will make an award of financial assistance from this announcement in the form of a cooperative agreement.

Estimated Amount and Length of Award

Cooperative Agreement Amount: \$1,500,000
 Projected Project Period 12 months [September 1, 2023 – August 31, 2024]

Financial Management and System of Internal Controls

If selected for funding, the NFE must:

- (a) Establish and maintain effective internal controls over the federal award that provides reasonable assurance that the non-federal entity is managing the federal award in compliance with federal statutes, regulations, and the terms and conditions of the federal award. These internal controls should be in compliance with the guidance in “Standards for Internal Control in the Federal Government,” issued by the Comptroller General of the United States and the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
- (b) Comply with federal statutes, regulations, and the terms and conditions of the federal awards.

- (c) Evaluate and monitor the non-federal entity's compliance with statute, regulations, and the terms and conditions of the federal awards.
- (d) Take prompt action when instances of noncompliance are identified, including noncompliance identified in audit findings.
- (e) Take reasonable measures to safeguard protected personally identified information and other information the federal awarding agency or pass-through entity designates as sensitive or the non-federal entity considers sensitive consistent with applicable federal, state, and local laws regarding privacy and obligations of confidentiality.

C. Eligibility Information

ONDCP encourages applications from non-profit organizations with expert knowledge and experience in developing or enhancing new or ongoing programs that aim to reduce drug overdose and related harms through strategic, evidence-based approaches.

Neither cost sharing nor matching are requirements for application eligibility.

D. Application and Submission Information

This application contains everything needed to apply for financial assistance from ONDCP.

Content and Form of Application Submission

Application Content

1. Eligibility:

ONDCP encourages applications from non-profit organizations (includes institutions of higher education and hospitals) with expert knowledge and experience in developing or enhancing new or ongoing programs that aim to reduce drug overdose and related harms through strategic, evidence-based approaches.

2. Technical Expertise and Experience:

Describe how the organization, its mission, and its submitted plan will contribute to the Administration's efforts to reduce drug overdose and other harms of substance (mis)use. Please include the organization's relevant experience and ability to research and analyze 1) existing community-based efforts to address the drug overdose epidemic and 2) current evidence-based and proven strategies to reduce drug overdose deaths and related harms. In addition, please describe your organization's ability to develop or enhance community-based programs that aim to reduce drug overdose and related harms. Also, document your organization's capacity to support the evaluation of community-based efforts to assess their efficacy in reducing drug overdose and other harms of opioid (mis)use, particularly in the regions of the United States with the highest rates of fatal and non-fatal drug overdoses. Finally, detail your organization's experience in supporting and promoting collaboration between public safety and public health agencies to ensure that drug overdose reduction

efforts are aligned and that communities benefit from a comprehensive and coordinated response.

3. Program Narrative:

The narrative must respond to the announcement and the specified criteria in Section E. The program narrative should be double-spaced, using standard 12-point font, with 1-inch margins and should not exceed 20 pages. Please number pages in the following manner: "1 of 20," "2 of 20," and so on.

The following sections should be included:

- Project design and implementation, including a plan and schedule for accomplishing the identified objectives;
- Capabilities and competencies; and
- The project timeline of each deliverable with the expected completion date and responsible person and/or organization.

4. Budget Detail Worksheet and Budget Narrative:

Applicant must provide an itemized budget for the cooperative agreement period. Applicant must submit budget worksheets and budget narrative in one file. At a minimum, the following categories must be addressed: Personnel, Fringe Benefits, Overtime, Travel, Facilities, Services, Equipment, Supplies, and Other Costs. The budget narrative should thoroughly and clearly describe every category of expense listed in the worksheet. Proposed budgets are expected to be complete and include all direct and indirect costs necessary for project activities related to the federal award. The budget should be, reasonable, in nature and amount, not exceeding that which would be incurred by a prudent person. It must be allowable, reflecting costs which are necessary for the performance of the federal award, consistent with policies and procedures that apply uniformly to both federally-financed and other activities of the non-federal entity and determined in accordance with generally accepted accounting principles in a cost-effective manner, and necessary for project activities. The narrative should be mathematically sound and correspond with the information and figures provided in the budget detail worksheet. The narrative should explain how costs were calculated and how they are relevant to the completion of the proposed project. (Also, see Section B for further information.)

5. Performance Measures:

The recipient will be required to provide to ONDCP quarterly progress reports on all required performance areas.

6. What an Application Must Include:

Applicants should anticipate that if they fail to submit an application that contains all the specified elements, it may negatively affect the review of their application; and, should a decision be made to make an award, it may result in the inclusion of special conditions that preclude the recipient from accessing or using award funds pending satisfaction of the conditions.

Moreover, applicants should anticipate that applications that are determined to be nonresponsive to the announcement, or that do not include the application elements that ONDCP considers to be critical, will neither proceed to peer review nor receive further consideration. The following elements are considered to be critical: Eligibility, Program Narrative, and Budget Detail Worksheet and Narrative.

ONDCP strongly recommends that applicants use appropriately descriptive file names (e.g., “Program Narrative,” “Budget Detail Worksheet,” “Budget Narrative,” “Timelines,” “resumes,” etc.).

The SF-424 is a required standard form used as a cover sheet for submission of pre-applications, applications, and related information. This funding opportunity **is not** subject to Executive Order 12372, Intergovernmental Review. (In completing the SF-424, applicants are to make the appropriate selection in response to question 19, indicating that the “Program is not covered by E.O. 12372.”)

Each applicant is required to (i) Be registered in the System for Award Management (SAM) before submitting its application; (ii) provide a valid Unique Entity Identifier (UEI) number in its application; and (iii) continue to maintain an active SAM registration with current information at all times during which it has an active federal award or an application or plan under consideration by ONDCP. ONDCP will not make an award until an applicant has fully complied with all applicable SAM and UEI requirements; and if the applicant has not so fully complied by the time ONDCP is ready to make award, ONDCP may determine that the applicant is not qualified to receive the award and use that determination as a basis for making award to another applicant.

See Section G for additional information.

7. Submission Dates and Times:

Applicants must register with [Grants.gov](#) prior to submitting an application. All applications are due to be submitted, and applicants must be in receipt of a successful validation message in [Grants.gov](#) by 5:00 p.m., Eastern Time, on August 31, 2023.

Cost Sharing and Match Requirements -

This announcement does not require a match. However, if a successful application proposes a voluntary match amount, and ONDCP approves the budget, the total match amount incorporated into the approved budget becomes mandatory and subject to audit.

Pre-Agreement Cost Approvals -

ONDCP does not typically approve pre-agreement costs; an applicant must request and obtain the prior written approval of ONDCP for all such costs. If approved, pre-agreement costs could be paid from Cooperative Agreement funds consistent with an Awardee's approved budget, and under applicable cost standards. However, all such costs prior to award and prior to approval of the costs are incurred at the sole risk of an applicant. Generally, no applicant should incur project costs before submitting an application requesting federal funding of these costs. Should there be extenuating circumstances that appear to be appropriate for ONDCP's consideration as pre-agreement costs, the applicant should contact the point of contact listed in the title page of this announcement for details on the requirements for submitting a written request for approval.

8. Other Submission Requirements:

For technical assistance with submitting an application, contact Grants.gov Customer Support Hotline at (800) 518-4726 or (606) 545-5035, or via email to support@grants.gov. The [Grants.gov](#) Support Hotline hours of operation are 24 hours a day, 7 days a week, except federal holidays.

Applicants who experience unforeseen Grants.gov technical issues that prevent them from submitting their application by the deadline must submit all required application materials to jdelano@ondcp.eop.gov no later than 5:00 p.m. on August 31, 2023, via email (including a brief explanation of the technical issues which prevented application through Grants.gov) and request approval for acceptance of the separate application.

For assistance with any other requirements of this solicitation, applicants may contact Jayme Delano, Office of National Drug Control Policy, by telephone at (202) 395-6794 or by email at jdelano@ondcp.eop.gov.

Also see Section G, How to Apply.

9. Limitation on Use of Award Funds for Employee Compensation; Waiver

With respect for any award in excess of \$250,000.00, made under this announcement, recipients may not use federal funds to pay total cash compensation (salary plus cash bonuses) to any employee of the award recipient at a rate that exceeds 110 percent of the maximum annual salary payable to a member of the Federal Government's Senior Executive Service (SES) at an agency with a Certified SES Performance Appraisal System for that year (this limitation does not apply to non-profit organizations specifically named at Appendix VIII to 2 C.F.R. part 200). The salary table for SES employees is available at [Salaries & Wages \(opm.gov\)](#). Note: A recipient may compensate an employee at a greater rate, provided the amount in excess of this compensation limitation is paid with non-federal funds. The limitation expressed herein is a budgetary limitation – that is, ONDCP will not reimburse salaries above the amount expressed.

The Director ONDCP may exercise discretion to waive, on an individual basis, the limitation on compensation rates allowable under award. An applicant requesting a waiver should

include a detailed justification in the budget narrative of the application. Unless the applicant submits a waiver request and justification with the application, the applicant should anticipate that ONDCP will request the applicant to adjust and resubmit the budget.

The justification should include the particular qualifications and expertise of the individual, the uniqueness of the service the individual will provide, the individual's specific knowledge of the program or project being undertaken with award funds, and a statement explaining that the individual's salary is commensurate with the regular and customary rate for an individual with his/her qualifications and expertise, and for the work to be done.

E. Application Review Information

1. Eligibility

ONDCP encourages applications from non-profit institution/organization (includes institutions of higher education and hospitals) with expert knowledge and experience in developing or enhancing new or ongoing programs that aim to reduce drug overdose and related harms through strategic, evidence-based approaches.

Federal awards greater than the simplified acquisition threshold will be reviewed and consider any information about the applicant that is in the designated integrity and performance system accessible through SAM (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)) (see 41 U.S.C. § 2313);

The applicant, at its option, may review information in the designated integrity and performance systems accessible through SAM and comment on any information about itself that a federal awarding agency previously entered and is currently in the designated integrity and performance system accessible through SAM. ONDCP will consider any comments by the applicant, in addition to the other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics, and record of performance under federal awards when completing the review of risk posed by applicants as described in § 200.205.

2. Merit Criteria

The merit of each application will be based on review of the following, with regard to scores, as addressed:

A. Initial Evaluation Criteria

Applications will not be further considered that fail to demonstrate the organization's expert knowledge and experience in conducting drug research and data analysis, developing or enhancing community-based programs to reduce drug overdose and related harms, evaluating such programs to ensure effectiveness, and supporting and promoting collaboration between public safety and public health agencies. ONDCP may enter into negotiations to seek clarification or to discuss perceived weaknesses. ONDCP may enter into negotiation where the budget and the budget narrative fail to demonstrate price reasonableness and/or price realism.

B. Specific Selection Criteria

Statement of Problem: Provide an understanding of the drug overdose epidemic and the need to implement or enhance community-based efforts to reduce drug overdose and related harms. (10 percent of 100)

Program Design and Implementation: Describe the overall goals, objectives, and deliverables for the Combating Overdose through Community-Level Intervention Initiative and identify strategies for designing and implementing all deliverables described herein. Include a timeline for completing tasks and responsible entity/person. (40 percent of 100)

Capabilities and Competencies: Describe the management structure, staffing, and in-house or contracted capacity to complete each of the deliverables/projects. Illustrate the ability to manage complex programs and projects effectively. Applicants must have expert knowledge and experience in expert knowledge and experience in conducting research and analysis, developing or enhancing community-based programs to reduce drug overdose and related harms, evaluating such programs to ensure effectiveness, and supporting and promoting collaboration between public safety and public health agencies. (40 percent of 100)

Budget and Budget Narrative: Provide a proposed budget and budget narrative that reconciles and is complete, reasonable and allowable, cost-effective, and necessary for project activities. ONDCP may enter into negotiations where the budget and the budget narrative fail to demonstrate price reasonableness and/or price realism. (Mandatory, therefore not specifically weighted.)

Performance Measure Data Collection: Provide proposed objectives and milestones for fulfilling the project's proposed deliverables. Ensure that the schedule for these objectives and milestones aligns with the timeline provided in the Program Design and Implementation section (described above). (10 percent of 100)

ONDCP and CDC will review applications against the established evaluation criteria, and ONDCP will make an award to the responsive applicant determined to offer the best value to ONDCP and the President's National Drug Control Program.

F. FEDERAL AWARD ADMINISTRATION INFORMATION

A notice of federal Award will be issued and is the authorizing document for the successful awardee to begin performance. Federal Financial Reports are required to be submitted quarterly, and within 90 days after the grant, activity is closed out. Program income must be accounted for and reported on the Federal Financial Reports.

Financial Management and System of Internal Controls

If selected for funding, the applicant must:

1. Establish and maintain effective internal controls over the federal award that provides reasonable assurance that the non-federal entity is managing the federal award in compliance with federal statutes, regulations, and the terms and conditions of the federal award. These internal controls should be in compliance with the guidance in "Standards for Internal Control in the Federal Government," issued by the Comptroller General of

the United States and the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

2. Comply with federal statutes, regulations, and the terms and conditions of the federal awards.
3. Evaluate and monitor the non-federal entity’s compliance with statutes, regulations, and the terms and conditions of the federal awards.
4. Take prompt action when instances of noncompliance are identified, including noncompliance identified in audit findings.
5. Take reasonable measures to safeguard protected personally identified information and other information the federal awarding agency or pass-through entity designates as sensitive or the non-federal entity considers sensitive consistent with applicable federal, state, and local laws regarding privacy and obligations of confidentiality.

G. Federal Awarding Agency Contacts

How to Apply

Applicants must register in, and submit applications through Grants.gov, a “one-stop storefront” to find federal funding opportunities and apply for funding. Find complete instructions on how to register and submit an application at www.Grants.gov. (More information is included in the “Contact Information” section of the title page.) Applicants who experience technical difficulties during this process should call Grants.gov Customer Support Hotline at **(800) 518-4726** or **(606) 545-5035**, 24 hours a day, 7 days a week, except federal holidays. Registering with Grants.gov is a one-time process; however, **processing delays may occur, and it can take several weeks** for first-time registrants to receive confirmation and a user password. ONDCP encourages applicants to **register several weeks before** the application submission deadline. In addition, ONDCP urges applicants to submit applications 72 hours prior to the application due date to allow time to receive validation messages or rejection notifications from Grants.gov and to correct, in a timely fashion, any problems that may have caused a rejection notification. Further, ONDCP strongly encourages all prospective applicants to sign up for Grants.gov email notifications regarding this announcement. If this announcement is cancelled or modified, individuals who sign up with Grants.gov for updates will be automatically notified.

Contact Information

For technical assistance with submitting an application, contact Grants.gov Customer Support Hotline at **(800) 518-4726** or **(606) 545-5035**, or via email to support@grants.gov. The Grants.gov Support Hotline hours of operation are 24 hours a day, 7 days a week, except federal holidays.

Applicants who experience unforeseen Grants.gov technical issues beyond their control that prevent them from submitting their application by the deadline must submit all required application materials to jdelano@ondcp.eop.gov no later than 5:00 p.m. on August 31, 2023, via email (including a brief explanation of the technical issues which prevented application through Grants.gov) and request approval for acceptance of the separate application.

For assistance with any other requirements of this solicitation, applicants may contact Jayme Delano, Office of National Drug Control Policy, by telephone at (202) 395- 6794 or by email at jdelano@ondcp.eop.gov.

H. Other Information

Applicant Disclosure of Pending Applications: Applicants are to disclose whether they have pending applications or awards for federally-funded cooperative agreements or sub-awards (including cooperative agreements) that include requests for funding to support the same or similar projects being proposed under this solicitation and will cover identical cost items outlined in the budget worksheet and narrative in the application under this announcement. The disclosure should include both direct applications for federal funding (e.g., applications to Federal agencies) and indirect applications for such funding (e.g., applications to State agencies that will sub-award federal funds). ONDCP seeks this information to help avoid any inappropriate duplication of funding. Leveraging multiple funding sources in a complimentary manner to implement comprehensive programs or projects is encouraged and is not seen as inappropriate duplication.

Disclosure of Lobbying Activities: All applicants must complete this information. Applicants that expend any funds for lobbying activities are to provide the detailed information requested on the form, “Disclosure of Lobbying Activities (SF-LLL). Applicants that do not expend any funds for lobbying activities are to enter “N/A” in the text boxes for Item 10 (“a. Name and Address of Lobbying Registrant” and “b. Individuals Performing Services”).

Awardees are required to electronically submit Federal Financial Reports (FFR) using the Department of Health and Human Services, Division of Payment Management (DPM). Completion of the Direct Deposit Form (SF-1199), available at <https://pms.psc.gov/>.

Cooperative Agreement funds cannot be used to supplant current funding of existing activities. “Supplant” is defined as replacing funding of a recipient’s existing program with funds from a federal grant.